What is Nectar?
Headquartered in New York City, Nectar operates at the intersection of clinical immunology and patient-centric digital health. The company provides comprehensive allergy testing, asthma management, and eczema treatment plans, catering to both pediatric and adult demographics. By integrating in-person clinical visits with online testing and immunotherapy options, Nectar addresses the growing demand for accessible, high-quality allergy care. Their market position is defined by a commitment to patient education and flexible care delivery, supported by a robust network of insurance partnerships that facilitate broader access to specialized medical services.
How much funding has Nectar raised?
Nectar has raised a total of $16.5M across 1 funding round:
Series A
$16.5M
Series A (2022): $16.5M with participation from The Obvious, Harmony Partners, and Juxtapose
Key Investors in Nectar
The Obvious
The Obvious Corp is a full-service creative and design firm that specializes in strategic communication, visual identity, and marketing collateral to help companies differentiate themselves in competitive markets.
Harmony Partners
Harmony Partners is a venture capital firm focused on providing flexible financing and strategic support to help innovative founders scale their businesses during expansion rounds.
Juxtapose
Juxtapose is an inception-stage investment firm that partners with experienced operators to build and scale category-defining technology companies from the ground up.
What's next for Nectar?
Following this major enterprise-level funding, Nectar is expected to prioritize the expansion of its clinical footprint and the refinement of its proprietary treatment protocols. The strategic allocation of capital will likely focus on enhancing the patient experience through technological advancements in remote monitoring and diagnostic accuracy. As the company matures, the focus will shift toward operational scaling and market penetration, leveraging its existing infrastructure to capture a larger share of the allergy and immunology market. Investors remain optimistic that Nectar's model of combining traditional clinical expertise with modern digital convenience will continue to drive long-term value and improved health outcomes for its patient base.
See full Nectar company page
